Vertex goes back to gene-editing partner — and science founder Feng Zhang — to add $1.2B deal on engineered cell therapies

John Carroll

Editor & Founder

Close to 3 years after Vertex helped Arbor Biotechnologies get off the ground with a reputation-building alliance to build gene-editing tools for a suite …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Vertex goes back to gene-editing partner — and science founder Feng Zhang — to add $1.2B deal on engineered cell therapies

John Carroll

Editor & Founder

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Novo Nordisk CEO to step down, timeline for successor unknown

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

It's been three months without a biotech IPO

RFK Jr. adopts new chikungunya vaccine guidance; other recommendations remain under review

Ver­tex goes back to gene-edit­ing part­ner — and sci­ence founder Feng Zhang — to add $1.2B deal on en­gi­neered cell ther­a­pies

Editor & Founder

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Vertex goes back to gene-editing partner — and science founder Feng Zhang — to add $1.2B deal on engineered cell therapies